Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice
about
Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalkThe pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axisTargeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesisDopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropesMechanisms for pituitary tumorigenesis: the plastic pituitary.Molecular interaction of BMP-4, TGF-beta, and estrogens in lactotrophs: impact on the PRL promoter.Dopamine-regulated adrenocorticotropic hormone secretion in lactating rats: functional plasticity of melanotropes.Genesis of prolactinomas: studies using estrogen-treated animalsPotential of gene therapy for the treatment of pituitary tumorsGenetically engineered mouse models of pituitary tumorsControl of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs.Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosagesAngiogenesis in pituitary adenomas: human studies and new mutant mouse models.What can we learn from rodents about prolactin in humans?Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary.Pituitary and brain dopamine D2 receptors regulate liver gene sexual dimorphismPTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.Pituitary hyperplasia: case series and literature review of an under-recognised and heterogeneous condition.Somatostatin is required for masculinization of growth hormone-regulated hepatic gene expression but not of somatic growthRegulation of pituitary hormones and cell proliferation by components of the extracellular matrix.Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis.Animal models of pituitary neoplasiaEach individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia.Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomasCurrent treatment options for hyperprolactinemia.The role of genetic and epigenetic changes in pituitary tumorigenesis.Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice.Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
P2860
Q24598902-23148332-1912-405D-B36A-EFDCA94F4ED8Q26772167-4CA3194C-61F1-4C9A-BAD3-F02833C38056Q28087609-2A731F3D-D5B7-4868-8DF7-294835368BD7Q28344662-2EA0F90F-4C73-441B-8B69-29DA2B9FF319Q28580699-A9CDE21F-DAC9-4FF7-9284-963378A3C638Q33630319-6EEF9853-7F3B-43BD-B920-7294E53CA69AQ33642161-C04FECE2-E412-4A33-A985-16A1EA0448A7Q33678305-7226CC87-0DAD-4212-B4C3-480458247E15Q33899741-B7CF38B9-46DD-4C5C-A649-FA44E739A342Q33899750-26CCED7A-B8DE-4063-AB65-BA1E6073E392Q33984418-E43A587F-711A-41EA-BD3D-65CFAF95AF59Q34394799-ACF35957-386F-4C1D-89F3-E9235BF9B0F2Q34532934-E5DA4A27-3E90-4B12-B998-6EF6CCD1D020Q34611189-F44DB345-0E62-4194-A8EF-5AD2FACE2608Q34721567-15B0CBA0-200E-4493-8464-A44D46A47D64Q34798387-28BE26C6-C032-406E-B057-B4607DACFA8BQ35046905-C6FD2BF5-767D-4C0A-8922-6AFAEC19A87DQ35088812-93A268B3-101E-4689-B0CC-25AC98C6A505Q35606471-8084E8DD-8A61-42FD-9214-58CE7D6CDDDAQ35786391-6A39794A-02A5-4721-BA97-B2BE24E98819Q36028536-319D47E6-9642-4188-8FBB-2FAC7E4ACE10Q36261711-A7D05941-3C00-409B-A39C-5A9A81F65BDEQ36447459-843A3DBA-2483-4A08-83FA-2931E7A7A083Q36486988-7EF20BC3-6165-4953-AB2B-D74561BCEB74Q36850160-FB3112D6-0CDE-4B70-BF49-11E398895DD0Q37162791-3370B824-5C35-45C9-8422-4832DBCDDCA1Q37240139-2D459E38-2B33-4FE6-94D7-BEEC5308C5DCQ38112205-750267A7-AD85-4D46-AFCB-0475962BD341Q38274982-30ABAF5A-59A1-420E-9F09-36FD2174CC2DQ42518626-15193C64-6FC5-441C-92D6-83601860B852Q44068922-C2EF5C5D-074C-4E4F-9100-025245F8BCC9
P2860
Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice
description
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1999
@ast
im November 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1999/11/01)
@sk
vědecký článek publikovaný v roce 1999
@cs
wetenschappelijk artikel (gepubliceerd op 1999/11/01)
@nl
наукова стаття, опублікована в листопаді 1999
@uk
مقالة علمية (نشرت في نوفمبر 1999)
@ar
name
Pituitary lactotroph adenomas ...... ine D2 receptor-deficient mice
@ast
Pituitary lactotroph adenomas ...... ine D2 receptor-deficient mice
@en
Pituitary lactotroph adenomas ...... ine D2 receptor-deficient mice
@nl
type
label
Pituitary lactotroph adenomas ...... ine D2 receptor-deficient mice
@ast
Pituitary lactotroph adenomas ...... ine D2 receptor-deficient mice
@en
Pituitary lactotroph adenomas ...... ine D2 receptor-deficient mice
@nl
prefLabel
Pituitary lactotroph adenomas ...... ine D2 receptor-deficient mice
@ast
Pituitary lactotroph adenomas ...... ine D2 receptor-deficient mice
@en
Pituitary lactotroph adenomas ...... ine D2 receptor-deficient mice
@nl
P2093
P356
P1433
P1476
Pituitary lactotroph adenomas ...... ine D2 receptor-deficient mice
@en
P2093
D. K. Grandy
M. A. Kelly
P304
P356
10.1210/ENDO.140.11.7118
P407
P577
1999-11-01T00:00:00Z